Search results
Results From The WOW.Com Content Network
Bova, a veterinary pharmaceuticals company based in the U.K. and Australia, began selling GS-441524, a drug compound to treat FIP, in 2021 — but the drug was not available for sale in the United ...
Bova, a veterinary pharmaceuticals company based in the U.K. and Australia, began selling GS-441524, a drug compound to treat FIP, in 2021 — but the drug was not available for sale in the United ...
The Bova Group sells GS-441524, a medication compound that can help treat FIP. However, the drug wasn’t available in the U.S. ... New Jersey-based Stokes Pharmacy noted that the Bova Group’s ...
GS-441524 is a nucleoside analogue antiviral drug which was developed by Gilead Sciences. It is the main plasma metabolite of the antiviral prodrug remdesivir , and has a half-life of around 24 hours in human patients.
Obeldesivir (GS-5245, ATV006) is an isobutyric ester prodrug of GS-441524 made by Gilead Sciences that is currently in Phase III trials for the outpatient treatment of COVID-19 in high risk patients. [ 1 ] [ 2 ] The purpose of the isobutyric ester modification on obeldesivir is to improve the oral bioavailability of the parent nucleoside, GS ...
Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. [23] The most common side effect in healthy volunteers is raised blood levels of liver enzymes. [13]
This antiinfective drug article is a stub. You can help Wikipedia by expanding it.
This list of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming their pharmaceutical drug candidates. . Pharmaceutical companies generally produce large numbers of compounds in the research phase for which it is impractical to use often long and cumbersome systematic chemical names, and for which the effort to generate nonproprietary ...